1 / 22

FARMAKOLOGI BEBAN STUDI = 3 SKS Kuliah = 2 SKS dan Praktikum = 1 SKS Dosen Pengasuh : 5 Orang

FARMAKOLOGI BEBAN STUDI = 3 SKS Kuliah = 2 SKS dan Praktikum = 1 SKS Dosen Pengasuh : 5 Orang GBPP SAP yang telah disepakati terdiri dari : 1. Farmakologi Umum (4 jam) 2. Obat ANS & Relaksasi otot (6 jam) 3. Obat Anestesi lokal & umum (4 jam) 4. Obat Diuretik (2 jam)

hanae-barron
Télécharger la présentation

FARMAKOLOGI BEBAN STUDI = 3 SKS Kuliah = 2 SKS dan Praktikum = 1 SKS Dosen Pengasuh : 5 Orang

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FARMAKOLOGI BEBAN STUDI = 3 SKS Kuliah = 2 SKS dan Praktikum = 1 SKS Dosen Pengasuh : 5 Orang GBPP SAP yang telah disepakati terdiri dari : 1. Farmakologi Umum (4 jam) 2. Obat ANS & Relaksasi otot (6 jam) 3. Obat Anestesi lokal & umum (4 jam) 4. Obat Diuretik (2 jam) 5. Obat Sedatif-Hipnotik & CNS Stimulan (2 jam) 6. Obat Analgesik, antipiretik & antiinflamasi (2 jam) 7. Obat Hemostatika (2 jam) 8. Hormon & Uterotonika (2 jam) 9. Histamin dan Antihistamin (2 jam)

  2. Pembobotan Penilaian Mata Kuliah : 1. Tugas : bobot 1,5 = 13,64% 2. Kuis/tentamen dll : bobot 1,5 = 13,64% 3. Soft skill : bobot 1 = 9,09% 4. UTS : bobot 2 = 18,8% 5. UAS : bobot 3 = 27,27% 6. Praktikum : bobot 2 = 18.18% bobot 11 = 100% Presensi : Wajib kuliah : Nilai E minimal 75% Nilai D,C & BC minimal 50%

  3. PRAKTIKUM (1 SKS) GBPP  SAP disepakati 6 materi praktikum : 1. Cara pemberian obat 2. Obat yg berpengaruh thd. Tekanan darah 3. Mengenal stadium anestesi umum 4. Obat yg berpengaruh pada Diuresis 5. Obat menurunkan rasa nyeri 6. Obat penghambat inflamasi. Presensi : Wajib Praktikum 100% Kelompok Praktikum  Dibagi 6 kelompok : A1 dari kelas A nomor urut 1-45 A2 dari kelas A nomor urut 46-69 B1 dari kelas B nomor urut 1-55 B2 dari kelas B nomor urut 56-70 C dari kelas C ; dan D dari kelas D

  4. GENERAL PHARMACOLOGY BY : D.K. Meles

  5. PHARMACOLOGY PHARMACON = Drug/ Poison LOGOS = Science PHARMACOLOGY : Science to Study of drug DRUG : All of substance to influence life system  application to prevent, diagnostic and therapeutics SCOPE OF PHARMACOLOGY - PHARMACOKINETIC PHARMACODYNAMIC PHARMACOTHERAPEUTIC PHARMACOGNOSI TOXICOLOGY

  6. DRUG  All of Substance to influence life process in use to prevent, therapeutics and diagnostic of disease. • Have criterion : 1. Effectiveness & Rivesible effect 2. Savety (Margin of savety)  Therapeutics Index. 3. High Selectivity

  7. PHARMACOKINETIC • ABSORPTION • DISTRIBUTION • BIOTRANSFORMATION • EXCRETION

  8. ABSORPSI OBAT : Moving Process or to remove of drug from tissue to another tissue  to cross the membrane with spesific mechanism. • TRANSPORT PASIVE Different Concentration, No need Energy, non spesific DIFFUSION NON-IONIC FILTRATION  POROUS FASCILITATIVE DIFFUSION  CARRIER • TRANSPORT ACTIVE OPPOSITION GRADIENS CONCENTRATION, Need Energy & Spesificity 3. PINOSITOSIS/ EXOSITOSIS/ ENDOSITOSIS.

  9. DRUG ABSORBTION  Account in % from drug dose • DRUG BIOAVAILABILITY Prosentage drug to reach site of action. Was count from dose of drug (for drug sistemik only). • FACTOR2 TO INFLUENCE RATE OF DRUG ABSORBTION : 1. Route of drug application 2. Circulation of place application drug. 3. Solubelity of drug 4. Ionization Rate of Drug 5. Broad of absorbtion area. 6. Size of molecule particle of drug 7. Drug Formulation

  10. ROUTE OF DRUG ADMINISTRATION 1. ENTERAL (SUBLINGUAL, PER-ORAL, PER-ANAL) 2. PARENTERAL (SC., IM., IV., INTRAPERITONEAL) 3. TOPICAL (SKIN, MUCOSA) 4. PERINHALATION. Sub-Lingual : Condition : Iritation, Damage by gastric Acid &Damage from drug metabolis.To clause  Dilute in saliva, Non-iritan & Lipofilik.

  11. PER-ORAL : • General, easy, safety and cheap. • Influenced by GIT motility • Absorbtion  Diffusi pasive, depend on rate of disolution & disintegration. • No application in consciousless. PER-RECTUM • Applicated in condition : gastric iritation, vomiting, damage by gastric acid. • Rate of absorbtion irreguler, Sometimes rectum irritation

  12. Per-injection : Benefid : Quick in absorbtion, vomit condition consciousless and emergency applicated Wickedness : must be sterilzation, can”t self uses, pain, & ralative more expensive. Intra-Vena : • No absorbtion process  direct in blood • Onset dan Duration  quickly • Iritatif drug can applicated • Drug toxicity  Low in therapeutics Index • Must be carefully

  13. Intra-muskuler (I.M.) dan Sub-kutan (S.C.) Condition : non-iritan drug, water soluble or suspention form. Quick in effect (im=Sc). Intraperitoneal : In animal experimental applicated only opten infection. Subtitute i.v. route Per-inhalation : • Use in gas form drug. • Absorbtion a cross epithel mucosa & quick. • Need tools/ specific methode • Dificult in dose count Topical  Unguentum, drops for mocosa & skin

  14. DRUG DISTRBUTION AFTER ABSORBTION  Extracelluler Fluids (Plasma + 4%,Interstesiil + 13%). DRUG  Protein plasma bound, Inactivation/ metabolism process,  Bound in reseptor Respon/ drug effect,  Exretion  Renal Intraseluler Fluid + 41% DRUG  Reseptor  drug respons  Prot. tissue.  Non Spesific & Reversibel.  Bound in Fat  Drug Reservoir.  Metabolism (Biotransformation). Drugs lipid soluble easy a cross membrane and distribution to intracelluler fluids, distribusi ke intraseluler. Opposite on non lipid soluble drug

  15. BIOTRANSFORMATION: MECHANISME TO CHANGE DRUGS STRUCTURE TO BE : * Decrease in fat solublelity * to break in ionized * Decrease in protein plasm/ tissue bound. Biotransformation  Drug to be in active Metabolite Aktive : Prontosil (In vitro)  Sulfanilamid. Proguanil  Metabilite aktif.

  16. MECHANISME OF BIOTRANSFORMATION • DRUG • ABSORBTION • DISTRIBUSTION protein bound • reseptor bound • Excretion • BIOTRANSFORMATION • (metabolism) • FASE I FASE II • Oksidation cytochrom axidase 1. Sulfation Sulfonyl transferase • Reduction Declorinasi 2. Glucorhonidation G.transferase • 3. HidrolysisEsterase, Amidase 3. Conjugation As.Glukoronat • 4. Hydrasi Hidrolase 4. AcetYlation, Methylation • BM < 300 BM> 300 BM< 300 • URINE • Filtration, Secretion

  17. PHARMAKODYNAMIC Pupose : To know drug effect To know drug Interaction To know spectrum drug respons MECHANISM OF ACTION : • Interaction with drug reseptor  to change biochemical & Physiological process ( Neurotransmitter) Respons. • Physical-chemist Characteristic of drug  Drug respons • Chelating Agent  drug respons • Drug incorporation with celluler structure  drug respon

  18. DRUGS INTERACTION • SYNERGISM  ADITIVE & POTENTIATIVE • ANTAGONISM : * A. Chemist : Heparin X Protamin * A. Functional/Physiological ( NE X Histamin) * A. Selective  Receptor – Drugs. A. Selective Competitive : In seem receptor. Riversible : ACH x Atropin Irreversible : NE x Prazosin A. Selective non-competitive  Different receptor, D-R bound can”t break in highly dose. Papaverin x Histamin ( Papaverin x ACH)

  19. DOSE : measure / quantity of drug to give for individual until a cross activity threshold but can”t cross Toxicity threshold. Margin Of safety = LD50 : ED50 INFLUANCE FACTOR OF DOSE : • BODY WEIGHT( BW) • OLD • RUST • SeX • Time of administration • Patological Disholder • Genetic factor • Tolerance

  20. DRUG TOXICITY • Wrong in drug administration : Tetracycline (I.V)  konvulsive. Penicilline (I.V.)  Presipitation. • To remain the drug effect ( Excessive dose/ Over dose, Ren & liver malfunction, genetic factor, drug interaction). • Hypersensitive reaction (Allergy) : Dermatitis, Asthma, Shyok anafilactic, damage in liver & ren, damage in bonemarrow. • Blood discrasia, as well as Leucopenia, aplastic anaemia, haemolytic anaemia, thrombositopenia. • Toxicity in liver & ren • Teratogenic effect.

  21. RESEARCH OF DRUG • TO INVENTION THE NEW DRUG  * EMPERICALLY * RASIONALITY * UNEXPECTED (KEBETULAN) * SCREENING PROCESS 2. PREKLINIK TRIAL  * Activity Test & Side effect Test * Uji Pharmacokinetic dan Pharmacodynamic * Uji Farmacy yang meliputi : * Uji Kualitative dan Kuantitative bahan * Uji Stability * Uji Sifat Physic dan Chemist * Uji drug formulation * Uji general toxicity : Uji Acute , Sub Acute & Chronic Toxicity Test * Uji specific toxicity : Uji Teratogenic, Mutagenic dan Carcinogenic 3. KLINICAL TRIAL  Devide 4 fase dan Uji Monitoring drug side effect (MESO).

  22. SEMOGA BERMANFAAT

More Related